| Name | Title | Contact Details |
|---|
Glengariff Health Care Ctr is a Glen Cove, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alternate Health (CSE: AHG, OTCQB: AHGIF) an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Alternate Health`s industry-leading software systems provide the platform for the company`s diverse operations, including blockchain tax collection systems, hemp-derived CBD product distribution, extract manufacturing and patient management systems for specialty clinics across North America. Through Alternate Health`s subsidiary, Blaine Labs, the Company is a leader in cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, including Walmart, Amazon, CVS and Walgreens. Alternate Health`s corporate office is located in Toronto, Canada, with additional offices in Venice, California, and San Antonio, Texas. The Company is well positioned to reinvest internal operating cash flow in its platform and product development over the long term, creating an attractive investment profile for its shareholders.
Northwestern Memorial Hospital (NMH) is one of the country's premier academic medical centers and is the primary teaching hospital of Northwestern University's Feinberg School of Medicine.
TDC Medical Inc is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.